Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 3/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 3/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028267 | 0.84 | L3MBTL1 (0.36) | RORCL3MBTL1ALDH1A1SLC6A1 | |
| SCHEMBL4024600 | 0.81 | L3MBTL1 (0.34) | RORCL3MBTL1ALDH1A1SLC6A1 | |
| SCHEMBL4026679 | 0.81 | L3MBTL1 (0.34) | RORCL3MBTL1ALDH1A1SLC6A1 | |
| SCHEMBL4028142 | 0.80 | RORC (0.39) | RORCALDH1A1 | |
| SCHEMBL4026859 | 0.78 | HTR1A (0.36) | DRD4RORCL3MBTL1ALDH1A1LMNA | |
| SCHEMBL4021193 | 0.77 | ALDH1A1 (0.37) | RORCALDH1A1 | |
| SCHEMBL4027189 | 0.75 | KCNH2 (0.35) | RORCALDH1A1LMNASLC6A1 | |
| SCHEMBL4020571 | 0.75 | KCNH2 (0.35) | RORCALDH1A1LMNASLC6A1 | |
| SCHEMBL4028852 | 0.74 | KCNH2 (0.37) | RORCALDH1A1LMNA | |
| SCHEMBL4022920 | 0.74 | RORC (0.40) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | PDE10A 2800/4885DRD4 2983/4885RORC 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.